Blood Test Shows Potential to Detect Advanced CTE in Living Players

A new blood test shows potential to detect advanced stages of chronic traumatic encephalopathy in the living, according to two recent studies published in the medical journal JAMA.

Diagnosing CTE in living patients has long been described by scientists as the holy grail of head trauma research. Until now, the degenerative brain disease linked to repeated blows in contact sports has been diagnosable only after death through autopsies.

One study published on Thursday by researchers at Boston University and Banner Health examined blood samples from 21 former football players who donated their brains to science, ESPN reported. Autopsies later confirmed CTE in 18 of those donors. Researchers identified a CTE marker by examining levels of a specific protein in the blood collected while the players were still alive.

The test showed promise only in identifying advanced stages of the disease rather than early cases. Patients in advanced stages typically experience memory loss, confusion, depression, and severe mood swings, while early stages often remain symptom-free.

Michael Alosco, co-director of clinical research at Boston University’s CTE Center and co-senior author of the study, called the test a “game changer” in the ability to diagnose the condition in living patients, as reported by ESPN. Alosco also told The Boston Globe that it is “a study of hope and optimism.”

Protein Markers and Study Findings

The BU and Banner Health study analyzed 21 deceased football players, including 12 who played professionally, seven who played through college, and two who played through high school. Autopsies showed that most of the former professionals, four college players, and one high school player had advanced-stage CTE.

Blood tests revealed higher protein concentrations in these cases, confirming the diagnosis. Five players who had both CTE and Alzheimer’s disease showed the highest levels of the targeted protein.

Blood Test Shows Potential to Detect Advanced CTE in Living Players
Photo: The Boston Globe

In a separate study published in JAMA on November 13, researchers from the Washington University School of Medicine in St. Louis identified the same blood biomarker, designated as eMTBR-tau243. Testing blood from 11 autopsy-confirmed CTE cases, the Washington University group found that the protein fragment elevated in Alzheimer’s disease was also present in advanced CTE cases.

Kanta Horie, co-senior author of the Washington University study, said that researchers are “potentially opening a new door for diagnosing and treating CTE in living patients,” according to The Guardian.

The BU researchers focused on combining biomarkers. Alosco explained to The Boston Globe that another biomarker, p-tau217, tracks closely with Alzheimer’s disease but not with CTE. Using both markers could eventually allow doctors to differentiate between the two neurodegenerative conditions.

Future Timeline and Medical Validation

Despite the breakthrough, experts emphasize that the research remains in an early discovery phase. Alosco told ESPN that he is “cautiously optimistic that we can really understand this finding and move it forward in the next five years or so.”

Dr. Michael Buckland, a clinical associate professor of pathology at the University of Sydney who was not involved in either study, called the findings “a watershed moment for the field, demonstrating that fluid biomarkers can work in assisting diagnosis of CTE in the living,” according to Scientific American. However, validation through larger cohorts is required before any public testing can begin.

Neurons with squiggly protein
Photo: Scientific American

Player Perspectives on Testing

The prospect of a living diagnosis raises complex questions for athletes currently playing contact sports. When ESPN surveyed more than 30 current and former NFL players about whether they would take a CTE test if one existed, responses varied widely.

“Yeah, I would,” Washington Commanders quarterback Marcus Mariota told ESPN. “I think because, at the end of the day, it gives insight to the rest of the NFL, to college kids, to high school kids of what we’re getting ourselves into.”

Other players expressed hesitation. Minnesota Vikings safety Joshua Metellus told ESPN, “I probably wouldn’t want [the test] while I’m in the league, because I think it’ll change the way I play. But I know there’s a lot of guys who are very curious and would like to know.”

An illustrative image of a traumatic brain injury model and X-ray. (Douglas Sacha/Getty Images)
Photo: WBUR

Questions About CTE Blood Tests

Can current blood tests diagnose CTE in living patients?

No standalone blood test is currently available or approved by the U.S. Food and Drug Administration. Recent studies in JAMA identified biomarkers that detect advanced CTE in autopsy-confirmed cases, but further validation through large-scale clinical trials is required.

Why can the new blood test only identify advanced CTE?

The identified protein markers concentrate at higher levels as tau tangles multiply and spread in the brain. Early-stage CTE produces lower concentrations of these proteins and often presents no clinical symptoms, making detection via current blood assays unreliable.

How do researchers distinguish CTE from Alzheimer’s disease?

Because both conditions involve abnormal tau protein accumulation, researchers are investigating combination panels using biomarkers like eMTBR-tau243 and p-tau217. A Washington University study published on November 13, 2026, highlighted how specific protein fragments overlap between the two neurodegenerative disorders.

The Boston University CTE Center originated as part of the school’s Alzheimer’s Disease Center established in 1996. In 2008, the center collaborated with the United States Department of Veteran Affairs and the Concussion Legacy Foundation to form a brain bank that officially opened that year as the first tissue repository in the world fully dedicated to the study of chronic traumatic encephalopathy.

It has since grown to become the largest repository focusing on traumatic brain injuries and chronic traumatic encephalopathy, housing 70% of global cases of the condition.

What are the next regulatory steps for a CTE test?

Boston University researchers estimate that validating the biomarker findings and moving toward Food and Drug Administration review could take approximately five years, contingent on broader studies involving living participants followed over time.